Developing a high-throughput method for the effecient selection of the highest producing cell is very important for the production of recombinant protein drugs. Here, we developed a novel transiently protein-anchored system coupled with fluorescence activated cell sorting (FACS) for the efficient selection of the highest producing cell. A furin cleavage peptide (RAKR) was used to join a human anti-epithelial growth factor antibody (aEGFR Ab) and the extracellular-transmembranecytosolic domains of the mouse B7-1 antigen (B7). The furin inhibitor can transiently switch secreted aEGFR Ab into a membrane-anchored form. After cell sorting, the level of membrane aEGFR Ab-RAKR-B7 is proportional to the amount of secreted aEGFR Ab in the medium. We further selected 23 aEGFR Ab expressing cells and demonstrated a high correlation (R 2 = 0.9165) between the secretion level and surface expression levels of aEGFR Ab. These results suggested that the novel transiently protein-anchored system can easily and efficiently select the highest producing cells, reducing the cost for the production of biopharmaceuticals.
Introduction
Using mammalian cell systems to produce recombinant protein drugs has become a mainstream practice in biopharmacy. Owing to the post-translational modification and glycosylation patterns of proteins, such systems often cannot be effectively replaced by other systems, whether bacterial, yeast, plant, or insect cell systems, such that more than 50% of the therapeutic proteins on the market are produced by mammalian cell systems [1, 2] . Determining the most effective method for screening the highest producing mammalian cells is one of the greatest challenges in the protein drug development process.
Limiting dilution cloning (LDC) is the most commonly used method due to its relative simplicity and low cost [3] . However, the whole process is time-consuming and labor-intensive, and only a few hundred clones can be certainly characterized, increasing the chance to lose highest producing cells. To overcome this problem, the fluorescence activated cell sorter (FACS) which can accurately analyze and separate single cells or specific subpopulations in short time has been increasingly used to identify high producing cells in the biopharmaceutical industries [4, 5] . Nevertheless, secreted proteins can usually not stay on cell surface, resulting in the difficult of measurement on single cells. Recently, researchers have developed different selection methods based on the co-expression of a non-fluorescent surface molecule (ex: CD20) [6] or a fluorescent intracellular protein (ex: GFP) [7] by inducing additional internal ribosome entry sites (IRESs) for reporter protein expression [8] . Some drawbacks, however, such as the possible cytotoxicity of fluorescent proteins [9] , the limitation of cell line specific characteristics [10] , and lower expression levels of downstream reporter proteins in the IRES system [11] , affect the accuracy of the selection of high-producing cells. Other methods which immobilize secreted proteins on a cell, including matrixbased secretion assay [12] , gel micro drop technology [13, 14] , and GPI-anchored systems [15] , require skillful laboratory personnel and expensive instruments, which may prevent their routine use [12] [13] [14] 16] . In short, a strategy that is easy to operate, low in cost, and FACS compatible is still unavailable for high proteinproducing cell selection.
In this study, we developed a novel transiently protein-anchored system coupled with FACS for efficient selection of the highest protein secreting cells. A furin cleavage peptide (RAKR) was used as a linker between a secreted aEGFR Ab and the extracellulartransmembrane-cytosolic domain of mouse B7-1 antigen (B7). The furin protease in the Golgi apparatus can efficiently cut the RAKR peptide to allow the aEGFR Ab to be secreted. Moreover, in the presence of furin inhibitor the secreted aEGFR Ab can be switched to a membrane-anchored aEGFR Ab-RAKR-B7 protein for screening the highest producing cell by FACS (Figure 1 ). First, RAKR fused secretory protein was confirmed to be released after the digestion by furin protease in the Golgi apparatus in HEK-293. Then, the switch of the secreted aEGFR Ab to an anchored form was examined in the presence of the furin inhibitor Dec-RVKR-CMK by using flow cytometry, ELISA, and western blot. Finally, we further selected 23 clones of aEGFR Ab expressing cells and calculated the correlation between the amounts of secreted aEGFR Ab and the membrane-anchored aEGFR Ab-RAKR-B7 levels. Positive results indicated that our system is a high-throughput method for the selection of the highest producing cells to meet the needs of biopharmaceutical markets.
Materials and Methods

Reagents and cells
Furin convertase inhibitor Decanoyl-Arg-Val-Lys-Arg-chloromethyl-ketone (Dec-RVKR-CMK) was purchased from Enzo Life Sciences, Inc. Human embryonic kidney 293 cells (HEK-293) were purchased from American Type Culture Collection (ATCC). The cells were cultured in Dulbecco minimal essential medium (Sigma-Aldrich) supplemented with 10% heat-inactivated bovine calf serum, penicillin (100 units/mL), and streptomycin (100 mg/ mL) at 37uC in a humidified atmosphere of 5% CO2. Phoenix cells were purchased from Orbigen. The cells were cultured in Dulbecco minimal essential medium F12 (Sigma-Aldrich) supplemented with 10% heat-inactivated fetal bovine serum, penicillin (100 units/mL), and streptomycin (100 mg/mL) at 37uC in a humidified atmosphere of 5% CO2.
Plasmid construction
The extracellular-transmembrane domain derived from mouse B7-1 antigen (B7) was described in a previous study [17, 18] . We created a furin cleavage site (RAKR) as a linker in the N-terminus of the extracellular-transmembrane-cytosolic domain of B7 by polymerase chain reaction. The complementary DNA sequence encoding furin cleavage site (RAKR sequence) and the extracellular-transmembrane domain of B7 were then constructed in pLKO-As3w-puro lentiviral vector.
The humanized anti-EGFR antibody h528 was described in the research of K. Makabe et al [19] . The V L and V H segments of humanized anti-EGFR antibody were synthesized by assembly polymerase chain reaction [20] . The complete light chain/heavy chain of the antibody was then established by fusion of the V L /V H segments with their constant region. The constant regions, including the C k and C H 1-hinge-C H 2-C H 3 domain, were cloned from complementary DNA prepared from Raji cells. The heavy chain and the light chain were joined by a FMDV 2A selfprocessing peptide [21] in the pLKO-As3w-puro lentiviral vector to generate pLKO-As3w-aEGFR Ab-RAKR-B7.
Generation of aEGFR Ab-secreting cell by lentiviral transduction
To produce pseudotyped lentiviruses, pLKO-As3w-aEGFR Ab-RAKR-B7 was co-transfected with pMD.G and pCMVDR8.91 to Phoenix cells (Orbigen) by TransIT-LT1 (Mirus). After transfection, the culture medium was filtered and collected in 24, 48, and 72 hours. Ten-fold concentrated medium containing lentivirus was mixed with 8 mg/ml polybrene (sigmaAldrich), and that mixture was added to HEK-293 cells. Following lentiviral transduction, cells were selected in puromycin-containing medium (1 mg/ml) to generate HEK-293/aEGFR cells that secreted aEGFR Ab in standard culture condition.
Western blotting analysis
HEK-293/aEGFR cells were cultured in serum-free DMEM medium containing furin inhibitor (0, 2, and 50 mM). After 24 hours, cultured medium and cells (5610 4 ) were collected and heated in reducing sample buffer at 100uC for 10 minutes. The samples were electrophoresed in an 8% SDS polyacrylamide gel under reducing conditions and then transferred onto a nitrocellulose paper (Millipore). After blocking in 5% skim milk, the membrane was incubated with 1 mg/mL horseradish peroxidaseconjugated goat anti-human IgG Fc antibody (Jackson ImmunoResearch Laboratories). The blots were washed three times with PBS-T (PBS containing 0.05% Tween 20) and twice with PBS before specific bands were visualized by enhanced chemiluminescence detection according to the manufacturer's instructions (Pierce).
Flow cytometry analysis
HEK-293 and HEK-293/aEGFR cells were cultured in serumfree DMEM medium containing furin inhibitor (20 mM). After 24 hours, cells were collected and washed by PBS. The expression level of anchored-aEGFR Ab-RAKR-B7 proteins was measured by staining cells with a FITC-conjugated goat anti-human IgGFcc antibody (Jackson ImmunoResearch Laboratories) in PBS containing 0.05% bovine serum albumin on ice. After removing unbound antibodies by extensive washing in PBS, the surface immunofluorescence of viable cells was measured with a flow cytometer (FACScalibur, BD Biosciences, Mountain View, CA) and fluorescence intensities were analyzed with CellQuest (BD Biosciences).
ELISA analysis
HEK-293 and HEK-293/aEGFR cells were seeded (1.5610 6 per well) overnight in 6-well plates. And then the cultured medium was shifted into serum-free DMEM medium or serum-free DMEM medium containing furin inhibitor (20 mM). The cultured medium was added to Maxisorp 96-well microplates (50 mL/well) for 1 hour at 37uC. Plates were then blocked with 5% skim milk in PBS for 1 hour at 37uC. After being washed, the wells were incubated with horseradish peroxidase (HRP)-conjugated antihuman IgG Fc antibody (Jackson ImmunoResearch Laboratories). The plates were washed three times with PBS-T and twice with PBS, and bound peroxidase was measured by adding 150 mL/well ABTS solution [0.4 mg/mL, 2,29-azinobis(3-ethylbenzthiazoline -6-sulfonic acid) (ABTS; Sigma-Aldrich), 0.003% H2O2, and 100 mM phosphate-citrate, pH = 4.0] for 30 min at room temperature. Color development was measured at 405 nm on a microplate reader. All the readings were background-adjusted by subtracting the absorbance of a blank control in the ELISA procedures.
Results
Furin inhibitor-mediated switch of the secreted aEGFR Ab into anchored form
The coding sequence of aEGFR Ab is joined to the mouse C2-type extracellular-transmembrane-cytosolic domains of the B7-1 receptor (B7) through a furin cleavage site (RAKR) to form aEGFR Ab-RAKR-B7 in a lentiviral vector. The HEK-293 cells were infected with lentiviral particles and selected with puromycin to obtain HEK-293/aEGFR cells. The furin protease in the Golgi apparatus can efficiently cut the RAKR linker in HEK-293/ aEGFR cells, allowing aEGFR Ab secretion. Only 2 amino acid residues (RA) of the furin cleavage site were left at the C-terminal end of the aEGFR Ab heavy chain after Golgi processing ( Figure 1B) .
To investigate whether the addition of the furin inhibitor (Dec-RVKR-CMK) [22] can switch the expression of the aEGFR Ab from secreted form to membrane form, HEK-293/aEGFR cells were treated with the furin inhibitor for 24 hours. The culture medium was collected and analyzed to determine the concentration of secreted aEGFR Ab by ELISA, while the surface level of aEGFR Ab-RAKR-B7 on the HEK-293 cells was analyzed simultaneously by flow cytometry. Figure 2A shows that HEK-293/aEGFR cells can continually secrete aEGFR Ab into cultured medium (0.85 pg/cell/day). After treatment of 20 uM furin inhibitor, the secretory level of aEGFR antibody was dramatically reduced (0.17 pg/cell/day). Similarly, Figure 2B shows that furin inhibitor treated HEK-293/aEGFR cells exhibited higher fluorescent intensity than the untreated cells. These results indicated that the furin inhibitor can efficiently modulate the switch of aEGFR Ab from secreted form to membrane-anchored aEGFR Ab-RAKR-B7 form in HEK-293/ aEGFR cells. To confirm the furin inhibitor-mediated uncleavage of aEGFR Ab-RAKR-B7 and the reduction of the secreted aEGFR antibody, the cultured medium and cell lysate of HEK-293/aEGFR cells with or without furin inhibitor were separated by SDS-PAGE under reducing condition and analyzed by western blotting using human Fc domain specific antibody. Figure 2C shows that most of the aEGFR antibodies in the culture medium were in the secreted form with apparent molecular weights of approximately 55 kDa and that the amount of antibody secretion was decreased with increasing furin inhibitor. In contrast, the expression level of aEGFR Ab-RAKR-B7 fusion proteins (95 kDa) in cell lysate was increased when the concentration of the furin inhibitor was increased. These results indicated that the furin inhibitor can successfully modulate the switch of aEGFR Ab from the secreted form to the anchored form by preventing the furinmediated cleavage of RAKR substrate peptide.
Good correction between the secreted and the membrane-anchored aEGFR Ab To assess whether the expression level of membrane aEGFR Ab-RAKR-B7 can reflect the amount of secreted aEGFR Ab, HEK-293/aEGFR cells were treated with furin inhibitor, and were sorted into three populations according to the high, medium, or low expression levels of membrane aEGFR Ab-RAKR-B7 detected by flow cytometry ( Figure 3A) . After the removal of the furin inhibitor, the amount of aEGFR Ab in the cultured medium was measured by ELISA. Figure 3B shows that the HEK-293/ aEGFR cells with high, medium, or low membrane aEGFR Ab-RAKR-B7 levels secreted 2.46, 0.91, and 0.22 pg/cell/day aEGFR Ab into the medium, respectively. These results indicated that the expression level of membrane aEGFR Ab-RAKR-B7 on the HEK-293/aEGFR cell is proportional to the amount of secreted aEGFR Ab in the medium.
The correlation between the secreted and the anchored aEGFR Ab of 23 selected clones
To further investigate the correlation of antibody titers between the secreted and the membrane-anchored aEGFR cells, HEK-293/aEGFR cells were sorted into 96-well plates at a density of one cell per well. Twenty-three HEK-293/aEGFR clones with various expression levels of membrane aEGFR Ab-RAKR-B7 were verified in the presence of furin inhibitors, and then selected for further analysis. The titers of secreted aEGFR Ab from these clones were measured by ELISA and plotted against the fluorescence intensity of respective membrane aEGFR Ab-RAKR-B7 in the presence of furin inhibitor. As shown in Figure 4 , there was a significant correlation, with a correlation coefficient of 0.9165, between the titer of secreted aEGFR Ab and the fluorescent intensity of membrane aEGFR Ab-RAKR-B7. Thus, the expression level of membrane aEGFR Ab-RAKR-B7 is thought to be representative of the productivity of secreted aEGFR Ab. These results suggested that the transiently proteinanchored system can be easily and efficiently used to select the highest protein-producing cells.
Discussion
Here, we describe a novel transiently protein-anchored system for efficient isolation of high producing mammalian cells. In the presence of furin inhibitor Dec-RVKR-CMK, the secreted aEGFR Ab can be transiently converted into the membraneanchored aEGFR Ab-RAKR-B7. Importantly, the level of secreted aEGFR Ab is strongly correlated with the level of the membrane-anchored aEGFR Ab-RAKR-B7, allowing us to accurately isolate the most productive clones. The strategy will provide an effective tool for screening the highest proteinproducing cell in a cost-effective and high throughput manner. Adapting this system to select the highest producing clone of cGMP banked CHO cells which stably secrete recombinant protein drugs will meet the requirements of the biopharmaceutical industry.
The tethering efficacy of the transmembrane domain-fused antibody was a critical concern in our screening system. Based on our previous studies, the optimized B7-1 membrane-tethered domain consists of a partial extracellular domain (143-245 a.a.) , a transmembrane domain (246-267 a.a.) , and an entire cytoplasmic tail (268-306 a.a.) [17, 18] . Two noteworthy issues of our construct were described as follows: First, the intact cytoplasmic tail is able to facilitate surface transportation of fusion proteins. Similar to previous reports, sorting elements of the cytoplasmic domain have indicated an ability to assist fused proteins for their translocation of proteins [23] . In addition, due to a lack of ER/Golgi retention signals, the cytoplasmic tail was revealed to lengthen the half-life of the tethered-proteins on the cell membrane [23] . Second, similar to many endogenous receptors that contained O-linked glycosylation residues, five glycosylations were observed in the extracellular domain (143-245 a.a.) of B7-1. Surface receptors has been rapid proteolyed once these O-linked glycosylations were removed. Thus, the retension of the extracellular domain was believed to be glycosylated and to able to stabilize the surface expression of fused proteins. Taken together, the antibody was fused to the optimalized membrane-tethered domain contained a glycosylated residue in the outer (exoplasmic) leaflet and an entire cytoplasmic sequence in the inner (cytoplasmic) leaflet. By using FACS, our fused antibody was confirmed to be stably expressed on the cell surface.
Although surface tethering is critical in high-throughput screening, massive and continual secretion of the target protein is the highest priority issue for industrial application. The furin cleavage sequence (-RAKR-) was used as a linker between the recombinant protein and the B7 membrane-tethered domain to meet both demands. Generally, furin localized in trans-Golgi network (TGN) is known to be involved in protein maturation [24] [25] [26] . Since all synthesized proteins were processed and sorted via TGN, recombinant proteins containing RAKR sequence should have been separated from the B7-1 tethering protein and consequently released into extracellular space. Based on previous studies, the furin cleavage sequence (-RAKR-) has also been applied as a linker in dual protein expression system. In their construct, two independent proteins, separated by a RAKR sequence, were coded from a single open reading frame and were capable of being effectively expressed. Similarly, a furin cleavage sequence (-RAKR-) has also been utilized in prevailing antibodyexpression vectors in industrial production [27] . Our transiently protein-anchored system also utilizes a RAKR sequence, combining it with a furin inhibitor for efficient selection of high protein or antibody producing cell lines. This will improve the efficiency of protein drug manufacturing for the global protein therapeutics market.
The transiently protein-anchored system can also be applied to mammalian cell display systems as an improved platform for protein evolution and for library screening. By constructing a transmembrane domain to the target protein that was derived from a cDNA library, several studies have exhibited highthroughput screening of the protein of interest on cell membranes by FACS [15, 28, 29] . For example, Ho and colleagues constructed an anti-CD22 scFv-PDGFR transmembrane domain combinatory library with a randomizing intrinsic antibody hot spot and then transfected the library into HEK-293T cells, allowing them to achieve high-throughput screening of a mutant clone with increasing binding affinity for CD22 [30] . However, the selected clones need extra cloning to obtain the free-form of the target protein, which may limit the sample size for further analysis. For instance, ELISA and Biacore analyses were required to determine the binding affinity of antibodies [31, 32] ; thus, the sketchy assessment or the small sample size may result in the loss of potential candidates. Compared to these systems, our transiently protein-anchored system makes it almost effortless to obtain the free-form of the target protein and offer a comprehensive platform for library screening.
Conclusions
The transiently protein-anchored system possesses several advantages, including: (1) The system makes it easy to modulate the construction of the recombinant protein (released or membrane-bounded) by using furin inhibitors; (2) The system can be combined with FACS to effectively collect cells with the highest level of target proteins; (3) Without complicated processes or procedures to immobilize secreted protein on a cell, the system enhances the speed of clone selection and effectively reduces the costs of meeting the requirements of biopharmaceutical markets; (4) The surface expression level of anchored proteins is highly proportional to the secretion level of proteins, providing an accurate indicator for clone selection; (5) This system can also be applied to mammalian cell display systems to improve the development of protein drugs, including for affinity maturation and the selection of antibodies, as well as for the revolution or activity improvement of enzymes. Overall, we believe that the transiently protein-anchored system should provide an easy-to-use, cost-effective, and high throughput tool for the production of recombinant proteins, and could accelerate the process required for protein drugs to enter clinical pharmaceutical markets.
